Grand Life Sciences

Grand Life Sciences is a leading Chinese pharmaceutical group with a focus on hemostasis, anesthesia & analgesia, wound management, immunity, infection, severe diseases, blood system disorders, and digestion. The company has multiple commercialized products including the market-leading hemocoagulase for injection in China’s hemostatic market; the first domestically-made targeted analgesic injection flurbiprofen axetil; and collagenase ointment—the only officially approved enzymatic debridement drug in China. Its subsidiary Yuanda Shuyang Pharmaceutical is among Asia’s largest blood product manufacturers with GMP/EU/WHO-compliant facilities exporting to over ten countries.